Airway soluble CSF1R predicts progression in patients with idiopathic pulmonary fibrosis

ERJ Open Res. 2023 Jul 17;9(4):00690-2022. doi: 10.1183/23120541.00690-2022. eCollection 2023 Jul.

Justin M Oldham¹, Kirk W Johnson², Gesa J Albers³, Emily Calamita³, Jordina Mah³, Poonam Ghai³, Richard J Hewitt^{3

4}, Toby M Maher^{3

5}, Philip L Molyneaux^{3

4}, Michael Huang², Adam J Byrne³

¹ Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
² AmMax Bio, Inc., Redwood City, CA, USA.
³ National Heart and Lung Institute, Imperial College London, London, UK.
⁴ Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
⁵ Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Abstract

This study provides the first evidence for a role of airway sCSF1R in IPF https://bit.ly/3KTBrCA.